REVIVA PHARMACEUTICALS HOLDINGS INC. - COMMON STO

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

14 أغسطس 2025 13:25:13 بحسب Nasdaq GlobeNewswire

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

26 يونيو 2025 05:40:56 بحسب Nasdaq GlobeNewswire

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

25 يونيو 2025 13:17:23 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

05 يونيو 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

02 يونيو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Participate in Upcoming Investor Conferences in May 2025

20 مايو 2025 05:00:01 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the A.G.P. Healthcare Company Showcase

13 مايو 2025 05:00:01 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the Citizens Life Sciences Conference

29 أبريل 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

24 أبريل 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

31 مارس 2025 13:05:15 بحسب Nasdaq GlobeNewswire

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

30 مارس 2025 08:30:00 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

04 فبراير 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the 2025 BIO CEO & Investor Conference

30 يناير 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

07 يناير 2025 05:00:01 بحسب Nasdaq GlobeNewswire

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

16 ديسمبر 2024 19:25:45 بحسب Nasdaq GlobeNewswire

Reviva Announces Proposed Public Offering

16 ديسمبر 2024 14:18:02 بحسب Nasdaq GlobeNewswire

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

16 ديسمبر 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 نوفمبر 2024 14:25:00 بحسب Nasdaq GlobeNewswire

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

12 نوفمبر 2024 05:00:02 بحسب Nasdaq GlobeNewswire

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

06 نوفمبر 2024 05:00:00 بحسب Nasdaq GlobeNewswire